Drug Information
Drug Generic Name | OMALIZUMAB |
Drug Class | ALLERGEN IMMUNOTHERAPY |
Chapter | Respiratory System |
Indications: prophylaxis of allergic asthma Cautions: autoimmune disease; susceptibility to helminth infection (discontinue if infection does not respond to anthelmintic). Hepatic impairment manufacturer advises caution—no information available. Renal impairment manufacturer advises caution (no information available). Pregnancy manufacturer advises avoid unless essential Breast-feeding manufacturer advises avoid (present in milk in animal studies). Side-effects : abdominal pain, headache, pyrexia. less commonly dyspepsia, nausea, diarrhoea, weight gain, postural hypotension, flushing, pharyngitis, bronchospasm, cough, syncope, paraesthesia, dizziness, drowsiness, malaise, influenza-like illness,photosensitivity, urticaria, rash, pruritus; rarely laryngoedema, parasitic infection, antibody formation; also reported arterial thromboembolic events, Churg- Strauss syndrome, thrombocytopenia, arthralgia, myalgia, joint swelling, alopecia, serum sickness (including fever and lymphadenopathy) Dose: By subcutaneous injection, ADULT and CHILD over 6 years, according to immunoglobulin E concentration and body-weight. |
|
Brand Name |
|